Today: Nov 14, 2024

AbbVie stocks tumble after schizophrenia drug disappoints

AbbVie stocks tumble after schizophrenia drug disappoints
November 11, 2024



AbbVie stocks tumble after schizophrenia drug disappoints  Monetary TimesAbbVie Inventory Tumbles on Failed Schizophrenia Drug Research. Bristol Myers Jumps.  Barron’sBristol Soars 11% As Traders Query AbbVie’s Expensive ‘Mistake’  Investor’s Industry DailyAbbVie Inventory Sinks After Schizophrenia Drug Trials Disappoint  InvestopediaAbbVie Tumbles After New Schizophrenia Drug Fails in Two Trials  Bloomberg

OpenAI
Author: OpenAI

Don't Miss

Discovery unearths how low-dose ketamine, a ‘lifesaving’ drug for primary melancholy, alleviates signs withing hours

Discovery unearths how low-dose ketamine, a ‘lifesaving’ drug for primary melancholy, alleviates signs withing hours

Those photographs reveal the other binding websites in NMDA receptors that the
Schizophrenia Dangers Tied to Psychedelic Use – Neuroscience Information

Schizophrenia Dangers Tied to Psychedelic Use – Neuroscience Information

Abstract: A brand new find out about hyperlinks hallucinogen-related emergency division visits